Merck & Co. (NYSE:MRK): Current price $44.60
Merck reports that the Biologics License Application for its investigational Timothy grass pollen allergy immunotherapy tablet, has been accepted for review by the FDA. In March, the firm also submitted a BLA to the FDA for its investigational ragweed pollen tablet. The application for Merck’s grass pollen tablet is supported by Phase III trials that studied the safety and efficacy of the investigational product, including a long-term, multi-season trial.
Microsoft Corporation (NASDAQ:MSFT): Current price $28.28
Microsoft is in negotiations to sell its IPTV business to Ericsson (NASDAQ:ERIC), and a deal could be reached in a few weeks, say inside sources to Bloomberg, which added that the division makes software used by phone companies including AT&T (NYSE:T) to deliver television over the Internet.
Pfizer (NYSE:PFE): Current price $28.54
KineMed reported the renewal of a non-exclusive research partnership with Pfizer to move forward novel approaches towards metabolic disease, and in particular Type II Diabetes. The collaboration will utilize KineMed’s unique dynamic proteomics tech platform to map out the impact of potential drug candidates upon specific metabolic pathways.
Don’t Miss: Intel Has Plans That Could Revolutionize Pay-TV.